NEW YORK, April 22, 2010 -- In an expansion of the firm's established healthcare research franchise, Jefferies
announced today the addition of Andrew Fein
as a Managing Director and Senior Equity Research Analyst covering Biotechnology companies.
Mr. Fein has more than ten years of experience as an analyst following the Biotechnology industry.
The hiring of Mr. Fein extends Jefferies' established coverage of Biotechnology, which includes senior analysts Thomas Wei and Eun Yang, Ph.D. in the US, and Peter Welford, CFA, Philippa Gardner, Eng.D. Tara Shivarattan, Ph.D. and James Vane-Tempest in Europe.
"Andrew Fein is a highly-regarded research analyst with strong relationships and a successful track record of covering Biotechnology companies," commented Steven R. Black, Global Head of Equity Research at Jefferies.
Mr. Fein was most recently at Piper Jaffray, where he was a Managing Director covering Biotechnology companies.
was a Managing Director covering Biotechnology companies at Collins Stewart (formerly C.E. Unterberg, Towbin) and held similar roles at Leerink Swann, J.P. Morgan and Deutsche Bank
He received a BA in Biology and History from Yale University.